Scott Gottlieb, who served as commissioner of the Food and Drug Administration (FDA) during President-elect Trump’s first ...

Goldman Sachs hosted a meeting with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

Trump administration pick for Health and Human Services department could cause rise in preventable disease, health expert ...

Mean duration of Crohn's disease was 7.4 years. Nearly half (48.5%) had previous biologic therapy failure, 45.7% had previous ...

Naomi Wolf is a truly heroic figure, and the publication of her great book The Pfizer Papers: Pfizer’s Crimes Against ...

One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent ...

Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

In Hong Kong, the 20-valent Pneumococcal Conjugate Vaccine (PCV20) that offers the broadest serotype coverage of any ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...